Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
|
|
Lineage Cell Therapeutics, Inc. (BTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/25/2022 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 20.7% stake in Lineage Cell Therapeutics, Inc. |
| 03/16/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/08/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/27/2020 |
SC 13D/A
| BIOTIME INC reports a 6.3% stake in ONCOCYTE CORPORATION |
| 02/14/2020 |
SC 13D/A
| GREENBELT CORP reports a 3.6% stake in Lineage Cell Therapeutics, Inc. |
| 01/06/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 09/13/2019 |
SC 13D/A
| BIOTIME INC reports a 16.2% stake in ONCOCYTE CORPORATION |
| 07/05/2019 |
SC 13D/A
| BIOTIME INC reports a 23.9% stake in ONCOCYTE CORPORATION |
| 03/12/2019 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 22.4% stake in BioTime, Inc. |
| 11/08/2018 |
SC 13D/A
| BIOTIME INC reports a 39.2% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 05/18/2018 |
SC 13D/A
| BIOTIME INC reports a 37.2% stake in ONCOCYTE CORPORATION |
| 04/03/2018 |
SC 13D/A
| BIOTIME INC reports a 38.8% stake in ONCOCYTE CORPORATION |
| 11/15/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/15/2017 |
SC 13D/A
| BIOTIME INC reports a 46.7% stake in ONCOCYTE CORPORATION |
| 04/03/2017 |
SC 13D/A
| BIOTIME INC reports a 44.4% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 02/17/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/10/2017 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/29/2016 |
SC 13D/A
| BIOTIME INC reports a 51.2% stake in ONCOCYTE CORPORATION |
| 03/03/2016 |
SC 13D/A
| BIOTIME INC reports a 56.8% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 02/22/2016 |
SC 13D/A
| BIOTIME INC reports a 60.2% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 09/16/2015 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 23.6% stake in BioTime, Inc. |
| 06/01/2015 |
SC 13D/A
| BIOTIME INC reports a 61.7% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 10/08/2014 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 21.7% stake in BioTime, Inc. |
| 08/19/2014 |
SC 13D/A
| Asterias Biotherapeutics, Inc. reports a 14.5% stake in BIOTIME, INC. |
| 06/18/2014 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 18.8% stake in BioTime, Inc. |
| 05/19/2014 |
SC 13D/A
| KINGSLEY ALFRED D reports a 13.3% stake in BIOTIME, INC. |
| 05/09/2014 |
SC 13D/A
| KINGSLEY ALFRED D reports a 14.4% stake in BIOTIME INC. |
| 05/02/2014 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 16.6% stake in BioTime, Inc. |
| 04/11/2014 |
SC 13D/A
| BIOTIME INC reports a 79.3% stake in ASTERIAS BIOTHERAPEUTICS, INC. |
| 12/30/2013 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 14.1% stake in BioTime, Inc. |
| 03/29/2013 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/29/2013 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/10/2013 |
SC 13D/A
| KINGSLEY ALFRED D reports a 18.9% stake in BIOTIME, INC. |
| 01/09/2013 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 17.1% stake in BioTime, Inc. |
|
|
|